Genetic Testing in Prostate Cancer: Considerations for Urologists and Their Patients Webcast (2020)
Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations.
To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate cancer.
The Genetic Testing in Prostate Cancer: Considerations for Urologists and their Patients Webinar will be recorded and available in webcast format on AUAUniversity and AUA’s YouTube channel. Additionally, the content will be released as an episode on AUA’s podcast. Learners will also be provided with links to access a patient and caregiver video and fact sheet produced by the Urology Care Foundation to increase patient understanding of genetic testing as it relates to prostate cancer, and facilitate enhanced patient – physician communications in regards to treatment options.
Support provided by independent educational grants from:
- Pfizer Inc.
After completing this activity, participants will be able to:
- State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
- Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
- Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.
- Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.
Education Council Disclosures
AUA Office of Education Staff has nothing to disclose.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 1.00 hours
Release Date: August, 2020
Expiration Date: August, 2021
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Non-Physician Participation